Literature DB >> 29531903

Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics.

Malinda Itchins1,2,3, Stephen Clarke1,2,3,4, Nick Pavlakis1,2,3,4.   

Abstract

Entities:  

Year:  2018        PMID： 29531903      PMCID： PMC5835640          DOI： 10.21037/tlcr.2018.01.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  24 in total

1.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Authors:  Tomoya Kawaguchi; Masahiko Ando; Kazuhiro Asami; Yoshio Okano; Masaaki Fukuda; Hideyuki Nakagawa; Hidenori Ibata; Toshiyuki Kozuki; Takeo Endo; Atsuhisa Tamura; Mitsuhiro Kamimura; Kazuhiro Sakamoto; Michihiro Yoshimi; Yoshifumi Soejima; Yoshio Tomizawa; Shun-ichi Isa; Minoru Takada; Hideo Saka; Akihito Kubo
Journal:  J Clin Oncol       Date:  2014-05-19       Impact factor: 44.544

2.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).

Authors:  Saulius Cicènas; Sarayut Lucien Geater; Petar Petrov; Yevgeniy Hotko; Gregory Hooper; Fan Xia; Nadejda Mudie; Yi-Long Wu
Journal:  Lung Cancer       Date:  2016-10-20       Impact factor: 5.705

4.  Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

Authors:  Dae Ho Lee; Keunchil Park; Joo Hang Kim; Jong-Seok Lee; Sang Won Shin; Jin-Hyoung Kang; Myung-Ju Ahn; Jin Seok Ahn; Cheolwon Suh; Sang-We Kim
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Authors:  Riichiroh Maruyama; Yutaka Nishiwaki; Tomohide Tamura; Nobuyuki Yamamoto; Masahiro Tsuboi; Kazuhiko Nakagawa; Tetsu Shinkai; Shunichi Negoro; Fumio Imamura; Kenji Eguchi; Koji Takeda; Akira Inoue; Keisuke Tomii; Masao Harada; Noriyuki Masuda; Haiyi Jiang; Yohji Itoh; Yukito Ichinose; Nagahiro Saijo; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

8.  Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

Authors:  Maurice Pérol; Christos Chouaid; David Pérol; Fabrice Barlési; Radj Gervais; Virginie Westeel; Jacky Crequit; Hervé Léna; Alain Vergnenègre; Gérard Zalcman; Isabelle Monnet; Hervé Le Caer; Pierre Fournel; Lionel Falchero; Michel Poudenx; Fabien Vaylet; Céline Ségura-Ferlay; Mojgan Devouassoux-Shisheboran; Miquel Taron; Bernard Milleron
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

9.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

Authors:  Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-Yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Journal:  Lancet       Date:  2008-11-22       Impact factor: 79.321

10.  Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

Authors:  Q Zhou; Y Cheng; J-J Yang; M-F Zhao; L Zhang; X-C Zhang; Z-H Chen; H-H Yan; Y Song; J-H Chen; W-N Feng; C-R Xu; Z Wang; H-J Chen; W-Z Zhong; Y-P Liu; Y-L Wu
Journal:  Ann Oncol       Date:  2014-10-03       Impact factor: 32.976
View more
  5 in total

1.  SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer.

Authors:  Yu-Jeong Choi; Kangwook Lee; Ji-Hye Yoon; Sung-Gook Cho; Yun-Gyeong Kim; Miso Jeong; Hyun-Ha Hwang; Seo Yeon Lee; Se-Eun Jung; Seong-Gyu Ko
Journal:  Biomed Res Int       Date:  2022-05-05       Impact factor: 3.246

2.  Model for predicting EGFR mutation status in lung cancer.

Authors:  Lam Nguyen Ho; Thuong Vu Le
Journal:  Breathe (Sheff)       Date:  2019-12

3.  Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.

Authors:  Nan Yao; Chen-Ran Wang; Ming-Qun Liu; Ying-Jie Li; Wei-Min Chen; Zheng-Qiu Li; Qi Qi; Jin-Jian Lu; Chun-Lin Fan; Min-Feng Chen; Ming Qi; Xiao-Bo Li; Jian Hong; Dong-Mei Zhang; Wen-Cai Ye
Journal:  Signal Transduct Target Ther       Date:  2020-10-09

Review 4.  Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.

Authors:  Gabriele Hintzen; Holger J Dulat; Erich Rajkovic
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

5.  Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.

Authors:  Rintu Thomas; Zhang Weihua
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.